The Dutch Oncology VC Specialist Aglaia has invested €3.4M in the Swiss Start-Up Inthera Bioscience for their Small molecule platform against solid tumors.
Aglaia is a venture capital firm based in Bilthoven (NL) which has 3 funds under their management for specialist investment into Oncology research. Last year they raised over €50M as part of its Oncology Fund II (which aims to grow to between €60-80M). Last month they also invested in a €9.68M Series A round Dutch-based InteRNA Technologies, a spin-off from the Hubrecht Institute, in Utrecht.
Founded in 2013 by Ulrich Kessler and Paramjit Arora, the Swiss biotech Inthera Bioscience employs a proprietary technology platform to rationally design protein-protein interaction inhibitors.
Inthera has discovered potent disruptors of hypoxia-inducible signaling (low oxygen indicators) for the treatment of solid tumors and targeted agents against HPV-associated cancer, which are in pre-clinical development. Examples of malignancies caused by the human papillomavirus include cervical, vaginal and penile cancers.
Hypoxia-inducible signaling is a major driver of cancer progression, since at low levels of oxygen tumors stimulate angiogenesis (blood vessel growth) and metastasis (spreading) in order to ‘survive’.